Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Phase 2
Completed
- Conditions
- Graft vs Host DiseaseMyelodysplastic SyndromesLeukemiaLeukemia, MyeloidLeukemia, Myelomonocytic, ChronicLeukemia, LymphocyticLymphomaLymphoma, Mantle-cellLymphoma, Non-HodgkinHodgkin Disease
- Interventions
- Drug: RFT5-SMPT-dgADrug: Isolex system
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-10-28
- Target Recruit Count
- 23
- Registration Number
- NCT00025662
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Phase 1
Completed
- Conditions
- Mycosis FungoidesSezary Syndrome
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 5
- Registration Number
- NCT00047060
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase 2
Completed
- Conditions
- Kidney Cancer
- Interventions
- Other: HLA Matched Peripheral BLood Stem Cells
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-06-19
- Target Recruit Count
- 156
- Registration Number
- NCT00003553
- Locations
- 🇺🇸
NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromeMyeloproliferative DisordersAcute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 202
- Registration Number
- NCT00003838
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
ACE Inhibition and Novel Cardiovascular Risk Factors
Phase 2
Completed
- Conditions
- Cardiovascular DiseasesHeart DiseasesHypertension
Vascular Interaction With Age in Myocardial Infarction
Not Applicable
Completed
- Conditions
- Myocardial Infarction
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
Phase 2
Completed
- Conditions
- Cardiomyopathy, HypertrophicHeart Hypertrophy
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 32
- Registration Number
- NCT00001965
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers
Completed
- Conditions
- Cardiomyopathy, HypertrophicCoronary DiseaseSyndrome XHealthyMyocardial Ischemia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 150
- Registration Number
- NCT00001459
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
Completed
- Conditions
- Arterial Occlusive DiseasesAtherosclerosisCytomegalovirus InfectionsCoronary Disease
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 355
- Registration Number
- NCT00001531
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Study of the Response of Human Small Blood Vessels
Phase 1
Completed
- Conditions
- HealthyHypertensionHypercholesterolemia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 87
- Registration Number
- NCT00001622
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath